8 research outputs found
Matrin 3 and Protein Localization in ALS
No full textabstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the deterioration of motor neurons. ALS affects about 1 in 20,000 people and leads to death within 2 to 5 years after diagnosis. There is currently no cure for ALS, but there are many genes known to be associated with ALS, such as SOD 1 and C9orf72. Recently, mutations in Matrin 3 were linked to ALS. While 15 mutations in Matrin 3 have been discovered, this study focuses on the four initial mutations, which are the Ser85Cys, Phe115Cys, Pro154Ser, and Thr622Ala mutations. This study attempts to understand the mechanism of how these mutations lead to ALS. The first aim focuses on the role of Matrin mutations in the mislocalization of TDP-43 from the nucleus to the cytoplasm, a pathological hallmark of ALS. We hypothesized expression of mutant Matrin 3 would lead to TDP-43 mislocalization, however the data did not support that hypothesis. The second aim of this study focuses on the mislocalization of TRanscription EXport (TREX) complex proteins within the nucleus. TREX proteins were studied based off of previous experiments suggesting that proteins within this complex bind to Matrin 3. The results showed differences in co-localization between each of these proteins and wild-type and mutant Matrin 3, confirming our earlier results. These findings can help increase our understanding of the mechanism of ALS while also setting the framework for future studies
ALS Linked Mutations in Matrin 3 Alter Protein-Protein Interactions and Impede mRNA Nuclear Export
No full textabstract: Exome sequencing was used to identify novel variants linked to amyotrophic lateral sclerosis (ALS), in a family without mutations in genes previously linked to ALS. A F115C mutation in the gene MATR3 was identified, and further examination of other ALS kindreds identified an additional three mutations in MATR3; S85C, P154S and T622A. Matrin 3 is an RNA/DNA binding protein as well as part of the nuclear matrix. Matrin 3 interacts with TDP-43, a protein that is both mutated in some forms of ALS, and found in pathological inclusions in most ALS patients. Matrin 3 pathology, including mislocalization and rare cytoplasmic inclusions, was identified in spinal cord tissue from a patient carrying a mutation in Matrin 3, as well as sporadic ALS patients. In an effort to determine the mechanism of Matrin 3 linked ALS, the protein interactome of wild-type and ALS-linked MATR3 mutations was examined. Immunoprecipitation followed by mass spectrometry experiments were performed using NSC-34 cells expressing human wild-type or mutant Matrin 3. Gene ontology analysis identified a novel role for Matrin 3 in mRNA transport centered on proteins in the TRanscription and EXport (TREX) complex, known to function in mRNA biogenesis and nuclear export. ALS-linked mutations in Matrin 3 led to its re-distribution within the nucleus, decreased co-localization with endogenous Matrin 3 and increased co-localization with specific TREX components. Expression of disease-causing Matrin 3 mutations led to nuclear mRNA export defects of both global mRNA and more specifically the mRNA of TDP-43 and FUS. Our findings identify ALS-causing mutations in the gene MATR3, as well as a potential pathogenic mechanism attributable to MATR3 mutations and further link cellular transport defects to ALS.Dissertation/ThesisDoctoral Dissertation Neuroscience 201
The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins
No full text\ua9 The Author(s) 2017. Amyotrophic lateral sclerosis (ALS) is characterized by the selective degeneration of motor neurons (MNs) and their target muscles. Misfolded proteins which often form intracellular aggregates are a pathological hallmark of ALS. Disruption of the functional interplay between protein degradation (ubiquitin proteasome system and autophagy) and RNA-binding protein homeostasis has recently been suggested as an integrated model that merges several ALS-associated proteins into a common pathophysiological pathway. The E102Q mutation in one such candidate gene, the endoplasmic reticulum (ER) chaperone Sigma receptor-1 (SigR1), has been reported to cause juvenile ALS. Although loss of SigR1 protein contributes to neurodegeneration in several ways, the molecular mechanisms underlying E102Q-SigR1-mediated neurodegeneration are still unclear. In the present study, we showed that the E102Q-SigR1 protein rapidly aggregates and accumulates in the ER and associated compartments in transfected cells, leading to structural alterations of the ER, nuclear envelope and mitochondria and to subsequent defects in proteasomal degradation and calcium homeostasis. ER defects and proteotoxic stress generated by E102Q-SigR1 aggregates further induce autophagy impairment, accumulation of stress granules and cytoplasmic aggregation of the ALS-linked RNA-binding proteins (RBPs) matrin-3, FUS, and TDP-43. Similar ultrastructural abnormalities as well as altered protein degradation and misregulated RBP homeostasis were observed in primary lymphoblastoid cells (PLCs) derived from E102Q-SigR1 fALS patients. Consistent with these findings, lumbar α-MNs of both sALS as well as fALS patients showed cytoplasmic matrin-3 aggregates which were not co-localized with pTDP-43 aggregates. Taken together, our results support the notion that E102Q-SigR1-mediated ALS pathogenesis comprises a synergistic mechanism of both toxic gain and loss of function involving a vicious circle of altered ER function, impaired protein homeostasis and defective RBPs
Author response image 3. PINCR-WT and PINCR-KO HCT116 cells were treated with 5-FU for 48 hr and the interaction between p53 and Matrin 3 was assessed by immunoblotting for p53 following IgG or Matrin 3 IP.
No full textAuthor response: Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to Matrin 3
No full textADHD IN ADULTS: COMORBODITY WITH BIPOLAR DISORDER AND SUBSTANCE ABUSE
No full textADHD is characterized by a continuous history of hyperactivity, forgetfulness, distractibility, impulsiveness and/or inattention, starting from the early childhood and at a more severe extent than whatever may be usual in peers. Originally described in pediatric populations, it is widely recognized in adults. While the disorder in children is mostly described as a disorder involving hyperactivity and impulsiveness, in adulthood ADHD inattention prevails on externalizing features, with a higher rate of psychiatric comorbidities, including major depressive disorder, bipolar disorder (BD), anxiety disorders and substance abuse (SUD).
Co-morbidity among ADHD, SUD and BD has been reported in many clinical and epidemiological studies. For this purpose we evaluated the prevalence of symptoms belonging to the ADHD spectrum in two samples of adult patients affected by SUD and by BD.
We found that one fifth of our sample of bipolar adults has a current diagnosis of ADHD, and that these patients are characterized by a greater number and more severe depressive episodes, resulting in a marked interference in global adaptation, when compared with ADHD subjects without bipolar. To complicate the clinical picture in BD + ADHD group, they are often associated with the Substance Use Disorder and the Impulse Control Disorder. Dual Diagnosis (BD+SUD) patient out of 4 reported childhood history of ADHD and more than 1 patient out of 2 presented corresponding symptoms at the time of observation. Our data are consistent with the observation that SUD in ADHD patients features an earlier onset, a longer duration and a faster progression towards substance polyabuse. In addition, the risk for developing a SUD is increased by the comorbidity of ADHD and BD. Our study confirms the observation that the relationship between adult ADHD and Substance Use Disorder is conveyed by the association with conduct disorders and antisocial personality disorder. Our data are consistent with the hypothesis that this relationship may also be facilitated by the presence of Bipolar Disorder. In conclusion, Bipolar Disorder, ADHD, Conduct Disorder and Substance Use Disorder may share a common diathesis conveyed by hyperactivity-impulsivity. Further prospective studies are needed to confirm our observations and to evaluate the influence of ADHD symptoms on course and treatment response
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study
No full textOBJECTIVES: Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations.
METHODS: SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses.
RESULTS: The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP. AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001].
CONCLUSION: Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study
No full textObjectives. Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations.Methods. SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses.Results. The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP.AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001].Conclusion. Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality
